Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.

Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133

Trastuzumab — Mechanism of Action and Use in Clinical Practice

Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,640

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793

Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 739

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer

Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 636

Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497

c-Met targeting in advanced gastric cancer: An open challenge

Marano, L., Chiari, R., Fabozzi, A., Vita, F. D., Boccardi, V., Roviello, G., Petrioli, R., Marrelli, D., Roviello, F., & Patriti, A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.028 · Cited by 81

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

Schuller, A. G., Barry, E., Jones, R. D. O., Henry, R. E., Frigault, M. M., Beran, G. J., Linsenmayer, D. C., Hattersley, M. M., Smith, A., Wilson, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2685 · Cited by 81

GD3 Synthase Expression Enhances Proliferation and Tumor Growth of MDA-MB-231 Breast Cancer Cells through c-Met Activation

Cazet, A., Lefebvre, J., Adriaenssens, É., Julien, S., Bobowski, M., Grigoriadis, A. E., Tutt, A. N. J., Tulasne, D., Bourhis, X. L., & Delannoy, P. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0302 · Cited by 81

Four-in-One Antibodies Have Superior Cancer Inhibitory Activity against EGFR, HER2, HER3, and VEGF through Disruption of HER/MET Crosstalk

Hu, S., Fu, W., Xu, W., Yang, Y., Cruz, M., Berezov, S. D., Jorissen, D., Takeda, H., & Zhu, W. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1670 · Cited by 80

Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases

Yan, S., Jiao, X., Zou, H., & Li, K. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0296-y · Cited by 80

Targeting the MET gene for the treatment of non-small-cell lung cancer

Gelsomino, F., Facchinetti, F., Haspinger, E. R., Garassino, M. C., Trusolino, L., de Braud, F., & Tiseo, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.11.006 · Cited by 77

Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression

Li, G., Zhao, L., Li, W., Fan, K., Qian, W., Hou, S., Wang, H., Dai, J., Wei, H., & Guo, Y. (2014) · Oncotarget · doi:10.18632/oncotarget.2135 · Cited by 77

Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer

Miranda, O., Farooqui, M., & Siegfried, J. M. (2018) · Cancers · doi:10.3390/cancers10090280 · Cited by 76

HER3/ErbB3, an emerging cancer therapeutic target

Zhang, N., Chang, Y., Rios, A. A., & An, Z. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv103 · Cited by 75

Resistance to Trastuzumab

Vivekanandhan, S., & Knutson, K. L. (2022) · Cancers · doi:10.3390/cancers14205115 · Cited by 80

Drug resistance in breast cancer: Mechanisms and strategies for management

Wu, G., Xiao, M., Hao, W.-C., Yang, Z., Liu, X., Xu, D., Peng, Z.-X., & Zhang, L. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101288 · Cited by 82

c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer

Delitto, D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8458 · Cited by 72

MET/HGF pathway activation as a paradigm of resistance to targeted therapies

Ko, B., He, T., Gadgeel, S. M., & Halmos, B. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.09 · Cited by 71

MicroRNAs in cancer drug resistance: Basic evidence and clinical applications

Ghasabi, M., Mansoori, B., Mohammadi, A., Duijf, P. H. G., Shomali, N., Shirafkan, N., Mokhtarzadeh, A., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26810 · Cited by 71

Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer

Lesniak, D. M., Sabri, S., Xu, Y., Graham, K., Bhatnagar, P. K., Suresh, M. R., & Abdulkarim, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071987 · Cited by 69

Stemming Resistance to HER-2 Targeted Therapy

Bedard, P. L., Cardoso, F., & Piccart, M. J. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9116-x · Cited by 68

Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer

Sun, C., Li, S., Zhang, F., Pan, J., Wang, L., Yang, C.-L., Xi, Y., & Li, D. (2016) · Oncotarget · doi:10.18632/oncotarget.7517 · Cited by 68

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Song, Z., Li, Y., Chen, S., Ying, S., Xu, S., Huang, J., Wu, D., Lv, D., Bei, T., Liu, S., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02245-z · Cited by 68

Abl interconnects oncogenic Met and p53 core pathways in cancer cells

Furlan, A., Stagni, V., Hussain, A., Richelme, S., Conti, F., Prodosmo, A., Destro, A., Roncalli, M. G., Barilà, D., & Maina, F. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.23 · Cited by 73

Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition

Okamoto, W., Okamoto, I., Yoshida, T., Okamoto, K., Takezawa, K., Hatashita, E., Yamada, Y., Kuwata, K., Arao, T., Yanagihara, K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0002 · Cited by 64

SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer

Chen, H., Libring, S., Ruddraraju, K. V., Miao, J., Solorio, L., Zhang, Z., & Wendt, M. K. (2020) · Oncogene · doi:10.1038/s41388-020-01488-5 · Cited by 64

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling

WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 64

A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy

Fan, X., Brezski, R. J., Fa, M., Deng, H., Greenplate, A. R., Gonzalez, A. O., Dubinsky, W. P., Strohl, W. R., Jordan, R. E., Zhang, N., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3240 · Cited by 63

A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population

Gow, C., Hsieh, M., Wu, S., & Shih, J. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.12.001 · Cited by 63

Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer

Chun, K., Park, J. H., & Fan, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_4 · Cited by 60

Copine-III interacts with ErbB2 and promotes tumor cell migration

Heinrich, C., Keller, C., Boulay, A., Vecchi, M., Bianchi, M., Sack, R., Lienhard, S., Duss, S., Hofsteenge, J., & Hynes, N. E. (2009) · Oncogene · doi:10.1038/onc.2009.456 · Cited by 61

Advanced HER2-positive gastric cancer: Current and future targeted therapies

Pazo-Cid, R., & Antón, A. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.08.008 · Cited by 61

Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer

Okines, A. F. C., & Cunningham, D. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12450246 · Cited by 60

Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors

Cohen, N. A., Zeng, S., Seifert, A. M., Kim, T. S., Sorenson, E. C., Greer, J. B., Beckman, M. J., Santamaria‐Barria, J. A., Crawley, M. H., Green, B. L., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2564 · Cited by 59

Better Together: Targeted Combination Therapies in Breast Cancer

Zanardi, E., Bregni, G., de Braud, F., & Cosimo, S. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.029 · Cited by 57

Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer

Moosavi, F., Giovannetti, E., Peters, G. J., & Firuzi, O. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103234 · Cited by 58

The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer

Lee, J. Y., Hong, M. E., Kim, S. T., Park, S. H., Kang, W. K., Kim, K.-M., & Lee, J. (2015) · Scientific Reports · doi:10.1038/srep09289 · Cited by 57

Understanding and circumventing resistance to anticancer monoclonal antibodies

Reslan, L., Dalle, S., & Dumontet, C. (2009) · mAbs · doi:10.4161/mabs.1.3.8292 · Cited by 57

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Gandullo‐Sánchez, L., Capone, E., Ocaña, A., Iacobelli, S., Sala, G., & Pandiella, A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911498 · Cited by 56

S100A14, a Member of the EF-hand Calcium-binding Proteins, Is Overexpressed in Breast Cancer and Acts as a Modulator of HER2 Signaling

Xu, C., Chen, H., Wang, X., Gao, J., Che, Y., Li, Y., Ding, F., Luo, A., Zhang, S., & Liu, Z. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.469718 · Cited by 56

Acquisition of chromosome instability is a mechanism to evade oncogene addiction

Salgueiro, L., Buccitelli, C., Rowald, K., Somogyi, K., Kandala, S., Korbel, J. O., & Sotillo, R. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910941 · Cited by 58

Resistance to human epidermal growth factor receptor type 2-targeted therapies

Théry, J., Spano, J., Azria, D., Raymond, É., & Penault-Llorca, F. M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.003 · Cited by 54

Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer

Scaltriti, M., Serra, V., Normant, E., Guzmán, M., Rodríguez, O., Lim, A. R., Slocum, K. L., West, K. A., Rodriguez, V., Prudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0966 · Cited by 54

The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance

Zhang, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107677 · Cited by 56

Ligand‐independent activation of MET through IGF‐1/IGF‐1R signaling

Varkaris, A. S., Gaur, S., Parikh, N. U., Song, J. H., Dayyani, F., Jin, J., Logothetis, C. J., & Gallick, G. E. (2013) · International Journal of Cancer · doi:10.1002/ijc.28169 · Cited by 53

Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)

Shimoyama, S. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.218 · Cited by 53

Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance

Raja, S. M., Luan, H., Naramura, M., Bailey, T., Clubb, R. J., Band, V., & Band, H. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.90442 · Cited by 53

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer

Shah, M. A., Kang, Y., Thuss-Patience, P. C., Ohtsu, A., Ajani, J. A., Cutsem, E. V., Hoersch, S., Harle-Yge, M.-L., & de Haas, S. L. (2019) · Gastric Cancer · doi:10.1007/s10120-018-00923-7 · Cited by 53

HGF–MET Cascade, a Key Target for Inhibiting Cancer Metastasis: The Impact of NK4 Discovery on Cancer Biology and Therapeutics

Mizuno, S., & Nakamura, T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14010888 · Cited by 52

MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition

Astanehe, A., Finkbeiner, M., Krzywinski, M. I., Fotovati, A., Dhillon, J., Berquin, I. M., Mills, G. B., Marra, M. A., & Dunn, S. E. (2012) · Oncogene · doi:10.1038/onc.2011.617 · Cited by 52

Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer

Kulkarni, S., Reddy, K. B., Esteva, F. J., Moore, H. C. F., Budd, G. T., & Tubbs, R. R. (2009) · Oncogene · doi:10.1038/onc.2009.422 · Cited by 55

Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer

Emde, A., Köstler, W. J., & Yarden, Y. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.09.002 · Cited by 52

Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive

Mishra, S., & Whetstine, J. R. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00652-15 · Cited by 53

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review

Zhong, H., Zhou, Z., Wang, H., Wang, R., Shen, K., Huang, R., & Wang, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413376 · Cited by 50

Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin Resistance

Gu, L., Waliany, S., & Kane, S. E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006220 · Cited by 50

C‐Met in invasive breast cancer

Ho-Yen, C., Green, A. R., Rakha, E. A., Brentnall, A. R., Ellis, I. O., Kermorgant, S., & Jones, J. L. (2013) · Cancer · doi:10.1002/cncr.28386 · Cited by 49

Role of HGF/MET axis in resistance of lung cancer to contemporary management.

Raghav, K. P. S., Gonzalez-Angulo, A. M., & Blumenschein, G. R. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.09.04 · Cited by 51

Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients

Ahmad, S., Gupta, S., Kumar, R., Varshney, G. C., & Raghava, G. P. S. (2014) · Scientific Reports · doi:10.1038/srep04483 · Cited by 51

Flavonoids as potential anti-hepatocellular carcinoma agents: Recent approaches using HepG2 cell line

Xia, J. (2013) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2013.v7.1.1 · Cited by 49

Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.

Zazo, S., Gónzález-Alonso, P., Martı́n-Aparicio, E., Chamizo, C., Cristóbal, I., Arpí, O., Rovira, A., Albanell, J., Eroles, P., Lluch, A. M., et al. (2016) · PubMed Central · Cited by 48

IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance

White, C. D., Li, Z., Dillon, D. A. R., & Sacks, D. B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.220939 · Cited by 47

Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment

Ghosh, S., Marrocco, I., & Yarden, Y. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.002 · Cited by 48

When the MET receptor kicks in to resist targeted therapies

Fernandes, M., Jamme, P., Cortot, A. B., Kherrouche, Z., & Tulasne, D. (2021) · Oncogene · doi:10.1038/s41388-021-01835-0 · Cited by 51

Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)

Miura, Y., Sukawa, Y., Hironaka, S., Mori, M., Nishikawa, K., Tokunaga, S., Okuda, H., Sakamoto, T., Taku, K., Nishikawa, K., et al. (2017) · Gastric Cancer · doi:10.1007/s10120-017-0725-6 · Cited by 44

HER2‐positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy

Ha, S. Y., Lee, J., Jang, J., Hong, J. Y., Do, I., Park, S. H., Park, J. O., Choi, M. G., Sohn, T. S., Bae, J. M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29159 · Cited by 45

‘Click’ synthesis of a triazole-based inhibitor of Met functions in cancer cells

Colombo, F., Tintori, C., Furlan, A., Borrelli, S., Christodoulou, M. S., Dono, R., Maina, F., Botta, M., Amat, M., Bosch, J., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.078 · Cited by 41

Overcoming Treatment Resistance in HER2-Positive Breast Cancer

Puglisi, F., Minisini, A. M., Angelis, C. D., & Arpino, G. (2012) · Drugs · doi:10.2165/11634000-000000000-00000 · Cited by 41

Changing strategies for target therapy in gastric cancer

Lee, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1179 · Cited by 40

The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents

Park, K. C., & Richardson, D. R. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129650 · Cited by 40

G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program

Mabe, N. W., Garcia, N. M. G., Wolery, S. E., Newcomb, R., Meingasner, R. C., Vilona, B. A., Lupo, R., Lin, C., Chi, J., & Alvarez, J. V. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108341 · Cited by 40

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

Jegg, A.-M., Ward, T. M., Iorns, E. J., Hoe, N., Zhou, J., Liu, X., Singh, S., Landgraf, R., & Pegram, M. D. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2252-9 · Cited by 39

Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance

Lamballe, F., Ahmad, F., Vinik, Y., Castellanet, O., Daian, F., Müller, A., Köhler, U. A., Bailly, A.-L., Josselin, E., Castellano, R., et al. (2020) · Advanced Science · doi:10.1002/advs.202003049 · Cited by 39

Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies

Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38

PD-L1 and c-MET expression and survival in patients with small cell lung cancer

Miao, L., Lu, Y., Xu, Y., Zhang, G., Huang, Z., Gong, L., & Fan, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9765 · Cited by 38

A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells

Chihara, Y., Shimoda, M., Hori, A., Ohara, A., Naoi, Y., Ikeda, J., Kagara, N., Tanei, T., Shimomura, A., Shimazu, K., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4382-6 · Cited by 38

Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance

Rezaei, Z., Sebzari, A., Kordi-Tamandani, D. M., & Dastjerdi, K. (2019) · DNA and Cell Biology · doi:10.1089/dna.2018.4427 · Cited by 38

Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer

Kim, J., Kim, D. K., Min, A., Lee, K.-H., Nam, H.-J., Kim, J. H., Kim, J.-S., Kim, T., Im, S., & Park, I. A. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2012-4 · Cited by 38

Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer

Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38

EGFR Expression in HER2-Driven Breast Cancer Cells

Weinberg, F., Peckys, D. B., & de Jonge, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239008 · Cited by 37

MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance

Paulson, A. K., Linklater, E. S., Berghuis, B. D., App, C. A., Oostendorp, L. D., Paulson, J. E., Pettinga, J., Melnik, M. K., Woude, G. F. V., & Graveel, C. R. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0042 · Cited by 38

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

Chia, S., Ellard, S. L., Mates, M., Welch, S. A., Mihalcioiu, C. L. D., Miller, W. H., Gelmon, K. A., Lohrisch, C. A., Kumar, V., Taylor, S., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0836-3 · Cited by 38

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer

Elshazly, A. M., & Gewirtz, D. A. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.09 · Cited by 35

Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma

Xu, Y., Peng, Z., Li, Z., Lü, M., Gao, J., Li, Y., Li, Y., & Shen, L. (2015) · BMC Cancer · doi:10.1186/s12885-014-1001-3 · Cited by 36

The Maxi-K (BK) Channel Antagonist Penitrem A as a Novel Breast Cancer-Targeted Therapeutic

Goda, A. A., Siddique, A. B., Mohyeldin, M. M., Ayoub, N. M., & Sayed, K. A. E. (2018) · Marine Drugs · doi:10.3390/md16050157 · Cited by 36

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

Vicencio, J. M., Evans, R., Green, R., An, Z., Deng, J., Treacy, C. A., Mustapha, R., Monypenny, J., Costoya, C., Lawler, K., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04701-3 · Cited by 33

Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer

Takahashi, N., Furuta, K., Taniguchi, H., Sasaki, Y., Shoji, H., Honma, Y., Iwasa, S., Okita, N. T., Takashima, A., Kato, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6753 · Cited by 35

Cancer Immunotherapy: The Dawn of Antibody Cocktails

Marrocco, I., Romaniello, D., & Yarden, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_2 · Cited by 36

Biological significance and targeting of c-Met tyrosine kinase receptor in cancer

Goetsch, L. (2012) · Frontiers in bioscience · doi:10.2741/4114 · Cited by 34

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3

Ebbing, E. A., Medema, J. P., Damhofer, H., Meijer, S. L., Krishnadath, K. K., Henegouwen, M. I. V. B., Bijlsma, M. F., & van Laarhoven, H. W. M. (2016) · Oncotarget · doi:10.18632/oncotarget.7200 · Cited by 34

Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds

Ikram, N., Mirza, M. U., Vanmeert, M., Froeyen, M., Salo‐Ahen, O. M. H., Tahir, M., Qazi, A. M., & Ahmad, S. (2019) · Biomolecules · doi:10.3390/biom9040124 · Cited by 34

Synthesis, antitumor evaluation and molecular docking studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives

Xu, F., Yang, Z.-Z., Jiang, J., Pan, W.-G., Yang, X., Wu, J., Zhu, Y., Wang, J. C. K., Shou, Q., & Wu, H.-G. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.05.007 · Cited by 34

MET and Small-Cell Lung Cancer

Gelsomino, F., Rossi, G., & Tiseo, M. (2014) · Cancers · doi:10.3390/cancers6042100 · Cited by 33

Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer

Mattos‐Arruda, L. D., & Cortés, J. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0187 · Cited by 34

A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer

Yang, L., Li, Y., Bhattacharya, A., & Zhang, Y. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav1620 · Cited by 32

Met interacts with EGFR and Ron in canine osteosarcoma

McCleese, J., Bear, M. D., Kulp, S. K., Mazcko, C. N., Khanna, C., & London, C. A. (2011) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2011.00309.x · Cited by 33

Targeting of Antigens to B Lymphocytes via CD19 as a Means for Tumor Vaccine Development

Ma, Y., Xiang, D., Sun, J., Ding, C., Liu, M., Hu, X., Li, G., Kloecker, G. H., Zhang, H., & Yan, J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203216 · Cited by 33

Chemically Synthetic Membrane Receptors Establish Cells with Artificial Sense-and-Respond Signaling Pathways

Wu, H., Zheng, L., Ling, N., Zheng, L., Du, Y., Zhang, Q., Liu, Y., Tan, W., & Qiu, L. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10903 · Cited by 32

Challenges and prospects in HER2-positive breast cancer-targeted therapy

Li, X., Zhang, X., Yin, S., & Nie, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104624 · Cited by 39

Attenuation of p53 mutant as an approach for treatment Her2-positive cancer

Fedorova, O., Daks, A. A., Shuvalov, O. Y., Kizenko, A., Petukhov, A., Gnennaya, Y., & Barlev, N. A. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00337-4 · Cited by 37

Artemin, a Member of the Glial Cell Line-derived Neurotrophic Factor Family of Ligands, Is HER2-regulated and Mediates Acquired Trastuzumab Resistance by Promoting Cancer Stem Cell-like Behavior in Mammary Carcinoma Cells

Ding, K., Banerjee, A., Tan, S. H., Zhao, J., Qian, Z., Li, R. Q., Qian, P., Liu, S., Wu, Z., Lobie, P. E., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.529552 · Cited by 32

Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers

Fink, M. Y., & Chipuk, J. E. (2013) · Genes & Cancer · doi:10.1177/1947601913488598 · Cited by 32

Mechanisms of Resistance to HER2 Target Therapy

Tortora, G. (2011) · JNCI Monographs · doi:10.1093/jncimonographs/lgr026 · Cited by 32

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations

Gebreyohannes, Y. K., Schöffski, P., Looy, T. V., Wellens, J., Vreys, L., Cornillie, J., Vanleeuw, U., Aftab, D. T., Dêbiec‐Rychter, M., Sciot, R., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0224 · Cited by 32

Evolving roles of MET as a therapeutic target in NSCLC and beyond

Lee, J. B., Shim, J. S. G., & Cho, B. C. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01051-9 · Cited by 34

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res

Shattuck, D. L., Miller, J. K., Carraway, K. L., III, & Sweeney, C. A. (2015)

Abstract 1821: HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer

Hashimoto, K., Macaulay, V. M., & Kong, A. H. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-1821

HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer

Hashimoto, K., Macaulay, V. M., & Kong, A. H. (2014) · Cancer Research

Metformin Enhances Trastuzumab Efficacy and Overcomes Resistance in HER2 Type Breast Cancer Cells.

Thor, A. D., Fan, Z., Yang, X., Esteva, F. J., Jones, F., Edgerton, S., Lind, S. M., & Liu, B. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-1133 · Cited by 2

The mechanism of HER2-amplified breast cancer with trastuzumab resistance and the research for novel therapy

Ren, Y. (2012) · Shengming kexue